2NO3

Novel 4-anilinopyrimidines as potent JNK1 Inhibitors


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.2 Å
  • R-Value Free: 0.276 
  • R-Value Work: 0.206 

wwPDB Validation 3D Report Full Report


This is version 1.3 of the entry. See complete history

Literature

Discovery of a new class of 4-anilinopyrimidines as potent c-Jun N-terminal kinase inhibitors: Synthesis and SAR studies.

Liu, M.Wang, S.Clampit, J.E.Gum, R.J.Haasch, D.L.Rondinone, C.M.Trevillyan, J.M.Abad-Zapatero, C.Fry, E.H.Sham, H.L.Liu, G.

(2007) Bioorg.Med.Chem.Lett. 17: 668-672

  • DOI: 10.1016/j.bmcl.2006.10.093

  • PubMed Abstract: 
  • A new series of 4-anilinopyrimidines has been synthesized and evaluated as JNK1 inhibitors. SAR studies led to the discovery of potent JNK1 inhibitors with good enzymatic activity as well as cellular potency represented by compound 2b. Kinase selecti ...

    A new series of 4-anilinopyrimidines has been synthesized and evaluated as JNK1 inhibitors. SAR studies led to the discovery of potent JNK1 inhibitors with good enzymatic activity as well as cellular potency represented by compound 2b. Kinase selectivity profile and the crystal structure of 2b are also described.


    Related Citations: 
    • Discovery of Potent, Highly Selective and orally bioavailable Pyridine Carboxamide C-jun NH2-terminal kinase inhibitors
      Zhao, H.,Serby, M.D.,Xin, Z.,Szczepankiewicz, B.G.,Liu, M.,Kosogof, C.,Liu, B.,Gum, R.J.,Clampit, J.E.,Haasch, D.L.
      (2006) J.Med.Chem. 49: 4455
    • Synthesis and SAR of 1,9-dihydro-9-hydroxypyrazolo[3,4-b]quinolin-4-ones as novel, selective c-Jun N-terminal kinase inhibitors.
      Liu, M.,Xin, Z.,Clampit, J.E.,Wang, S.,Gum, R.J.,Haasch, D.L.,Trevillyan, J.M.,Abad-Zapatero, C.,Fry, E.H.,Sham, H.L.
      (2006) Bioorg.Med.Chem.Lett. 16: 2590
    • Selective aminopyridine-based C-Jun N-terminal kinase inhibitors with cellular activiy
      Szczepankiewicz, B.G.,Kosogof, C.,Nelson, L.T.J.,Liu, G.,Zhao, H.,Serby, M.D.,Xin, Z.,Liu, B.,Gum, R.J.,Haasch, D.
      (2006) J.Med.Chem. 49: 3563


    Organizational Affiliation

    Metabolic Disease Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064-6098, USA. mei.liu@abbott.com




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Mitogen-activated protein kinase 8
A, B
370Homo sapiensMutation(s): 2 
Gene Names: MAPK8 (JNK1, PRKM8, SAPK1, SAPK1C)
EC: 2.7.11.24
Find proteins for P45983 (Homo sapiens)
Go to Gene View: MAPK8
Go to UniProtKB:  P45983
Entity ID: 2
MoleculeChainsSequence LengthOrganismDetails
C-JUN-AMINO-TERMINAL KINASE-INTERACTING protein 1
F, G
11N/AMutation(s): 0 
Protein Feature View is not available: No corresponding UniProt sequence found.
Small Molecules
Ligands 2 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
SO4
Query on SO4

Download SDF File 
Download CCD File 
A, B
SULFATE ION
O4 S
QAOWNCQODCNURD-UHFFFAOYSA-L
 Ligand Interaction
859
Query on 859

Download SDF File 
Download CCD File 
A, B
2-({2-[(3-HYDROXYPHENYL)AMINO]PYRIMIDIN-4-YL}AMINO)BENZAMIDE
C17 H15 N5 O2
QHPKKGUGRGRSGA-UHFFFAOYSA-N
 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
859IC50: 9 - 170 nM (99) BINDINGDB
859IC50: 9 nM PDBBIND
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.2 Å
  • R-Value Free: 0.276 
  • R-Value Work: 0.206 
  • Space Group: P 32 2 1
Unit Cell:
Length (Å)Angle (°)
a = 157.201α = 90.00
b = 157.201β = 90.00
c = 123.362γ = 120.00
Software Package:
Software NamePurpose
CNXphasing
HKL-2000data scaling
HKL-2000data reduction
CNXrefinement
MAR345data collection

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

  • Deposited Date: 2006-10-24 
  • Released Date: 2007-04-17 
  • Deposition Author(s): Abad-Zapatero, C.

Revision History 

  • Version 1.0: 2007-04-17
    Type: Initial release
  • Version 1.1: 2008-05-01
    Type: Version format compliance
  • Version 1.2: 2011-07-13
    Type: Version format compliance
  • Version 1.3: 2017-10-18
    Type: Refinement description